Ypsomed Holding AG (XSWX:YPSN) Research & Development: CHF40.0 Mil (TTM As of Mar. 2026)


XSWX:YPSN Ypsomed Holding AG XSWX:YPSN
91 GF Score
Price CHF353.00
GF Value CHF397.48
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Ypsomed Holding AG Research & Development?

Ypsomed Holding AG XSWX:YPSN +1.91% 91 Research & Development is CHF40.0 Mil as of Mar. 2026. GuruFocus rates XSWX:YPSN with a GF Score™ of 91/100 and a GF Value™ of CHF397.48 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Ypsomed Holding AG's Research & Development for the six months ended in Mar. 2026 was CHF21.1 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was CHF40.0 Mil.

Ypsomed Holding AG  (XSWX:YPSN) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Ypsomed Holding AG Research & Development Related Terms

Ypsomed Holding AG Research & Development Historical Data

* Premium members only.

The historical data trend for Ypsomed Holding AG's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ypsomed Holding AG Research & Development Chart

Ypsomed Holding AG Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 30.48 33.55 40.02

Ypsomed Holding AG Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 15.38 18.17 18.88 21.14
XSWX:YPSN
91GF Score
Ypsomed Holding AG XSWX:YPSN
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ypsomed Holding AG Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF40.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of CHF40.0 Mil mean?
Ypsomed Holding AG (XSWX:YPSN) has a Research & Development of CHF40.0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Ypsomed Holding AG and its competitors.
Is Ypsomed Holding AG's Research & Development too high?
Ypsomed Holding AG's current Research & Development is CHF40.0 Mil. Overall, Ypsomed Holding AG has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ypsomed Holding AG's Research & Development compare to ISRG and BDX?
Ypsomed Holding AG's Research & Development of CHF40.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Ypsomed Holding AG and its competitors. Ypsomed Holding AG's current Research & Development is CHF40.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ypsomed Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Ypsomed Holding AG (XSWX:YPSN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF397.48, compared to a current price of CHF353.00 — trading 11.2% below its estimated fair value. The current Research & Development is CHF40.0 Mil. Ypsomed Holding AG's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Ypsomed Holding AG (XSWX:YPSN), the current Research & Development is CHF40.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ypsomed Holding AG (XSWX:YPSN) Overvalued in 2026?

Based on GuruFocus' analysis, Ypsomed Holding AG stock appears to be undervalued. The current stock price of CHF353.00 is trading 11.2% below its estimated GF Value™ of CHF397.48. GuruFocus considers Ypsomed Holding AG to be Modestly Undervalued.

Key valuation signals for XSWX:YPSN:

  • Research & Development: CHF40.0 Mil
  • GF Value™: CHF397.48 vs. price of CHF353.00 (11.2% below fair value)
  • GF Score™: 91/100 with 3 warning signs

No single metric tells the full story. See the XSWX:YPSN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ypsomed Holding AG Business Description

Other Exchanges YPSNz:UK0QLQ:UKOWX:Germany
Address Brunnmattstrasse 6, Burgdorf, CHE, 3401
Ypsomed Holding AG is a Swiss company that develops and manufactures injection and infusion systems that allow patients to self-administer medication. Specifically, the company focuses on ensuring the ease of diabetes and insulin injection. The company offers various products such as pen needles with a click-on function. The company operates under two reportable segments: Ypsomed Delivery Systems and Ypsomed Diabetes Care.
91GF Score

Get the complete analysis for XSWX:YPSN

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF353.00
Price
CHF397.48
GF Value